- Home
- VYGR vs OCGN Comparison
VYGR vs OCGN Comparison
Compare VYGR & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- OCGN
- Stock Information
- Founded
- VYGR 2013
- OCGN 2013
- Country
- VYGR United States
- OCGN United States
- Employees
- VYGR N/A
- OCGN N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VYGR Health Care
- OCGN Health Care
- Exchange
- VYGR Nasdaq
- OCGN Nasdaq
- Market Cap
- VYGR 222.9M
- OCGN 189.6M
- IPO Year
- VYGR 2015
- OCGN N/A
- Fundamental
- Price
- VYGR $3.41
- OCGN $0.68
- Analyst Decision
- VYGR Strong Buy
- OCGN Strong Buy
- Analyst Count
- VYGR 9
- OCGN 3
- Target Price
- VYGR $14.86
- OCGN $6.33
- AVG Volume (30 Days)
- VYGR 360.5K
- OCGN 4.2M
- Earning Date
- VYGR 03-11-2025
- OCGN 03-05-2025
- Dividend Yield
- VYGR N/A
- OCGN N/A
- EPS Growth
- VYGR N/A
- OCGN N/A
- EPS
- VYGR N/A
- OCGN N/A
- Revenue
- VYGR $80,001,000.00
- OCGN $4,054,999.00
- Revenue This Year
- VYGR N/A
- OCGN N/A
- Revenue Next Year
- VYGR $23.46
- OCGN N/A
- P/E Ratio
- VYGR N/A
- OCGN N/A
- Revenue Growth
- VYGR N/A
- OCGN N/A
- 52 Week Low
- VYGR $3.56
- OCGN $0.52
- 52 Week High
- VYGR $10.66
- OCGN $2.08
- Technical
- Relative Strength Index (RSI)
- VYGR 28.74
- OCGN 53.03
- Support Level
- VYGR $3.58
- OCGN $0.69
- Resistance Level
- VYGR $3.96
- OCGN $0.80
- Average True Range (ATR)
- VYGR 0.25
- OCGN 0.05
- MACD
- VYGR -0.01
- OCGN 0.02
- Stochastic Oscillator
- VYGR 2.60
- OCGN 58.35
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").